Show simple item record

dc.contributor.authorSchroë, H.
dc.contributor.authorHolden, A.
dc.contributor.authorGoueffic, Y.
dc.contributor.authorJansen, Shirley
dc.contributor.authorPeeters, P.
dc.contributor.authorKeirse, K.
dc.contributor.authorIto, W.
dc.contributor.authorVermassen, F.
dc.contributor.authorMicari, A.
dc.contributor.authorBlessing, E.
dc.contributor.authorJaff, M.
dc.contributor.authorZeller, T.
dc.identifier.citationSchroë, H. and Holden, A. and Goueffic, Y. and Jansen, S. and Peeters, P. and Keirse, K. and Ito, W. et al. 2018. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study. Catheterization and Cardiovascular Interventions. 91 (3): pp. 497-504.

© 2017 The Authors. Catheterization and Cardiovascular Interventions Published by Wiley Periodicals, Inc. Objectives: The purpose of this study was to assess the safety and performance of Stellarex Drug-coated balloon (DCB). Background: DCB coatings differ in excipients, paclitaxel dose, and coating morphologies. Due to these differences, a class effect with DCBs has not been demonstrated. Consequently, each DCB needs to be evaluated independently based on its own clinical study results. Methods: The ILLUMENATE Global Study is a prospective, multicenter, single-arm study. Patients with intermittent claudication or ischemic rest pain due to superficial femoral artery (SFA) and/or popliteal peripheral artery disease (PAD) were treated with the Stellarex DCB. The primary efficacy endpoint was primary patency, defined as freedom from restenosis with peak systolic velocity ratio =2.5 or clinically-driven target lesion revascularization (CD-TLR) at 12 months. The primary safety endpoint was freedom from device and procedure-related death through 30 days postprocedure and freedom from target limb major amputation and CD-TLR through 12 months. Results: In total, 417 lesions were treated in 371 patients. The mean lesion length was 7.5 ± 5.3 cm, 40.8% of lesions were severely calcified per core laboratory fluoroscopy criteria and 31.3% were total occlusions. Primary patency by independent duplex core lab evaluation was 81.4% and the freedom from CD-TLR was 94.8% day 365 per Kaplan-Meier estimate. The majority of patients experienced improvements in their Rutherford classification (90.3%) and walking impairment questionnaire score (83.6%) at 12 months compared to baseline. Conclusions: This study validated previous positive findings and confirms the strong safety profile and effectiveness outcomes.

dc.titleStellarex drug-coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study
dc.typeJournal Article
dcterms.source.titleCatheterization and Cardiovascular Interventions
curtin.departmentCurtin Medical School
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record